Kiniksa Pharmaceuticals International, plc reported $754M of revenue over the trailing twelve months, +57% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $754M (to Q1 2026). Net income: $73M, trailing twelve months to Q1 2026. Free cash flow: $164M, trailing twelve months to Q1 2026. Operating margin: 12%, trailing twelve months to Q1 2026.

KNSAKiniksa Pharmaceuticals International, plc

Healthcare

$79.76+125% 1Y

$79.76

$35.5152 weeks$80.83

KNSA as reported

Kiniksa Pharmaceuticals International, plc reported $754M of revenue over the trailing twelve months, +57% on the year before. 10 reported series are charted on this page, each one as filed.

$754M

Revenue, trailing twelve months · to Q1 2026 · +57% against the twelve months before

Net income: $73M
Net income · −531% year on year · trailing twelve months to Q1 2026
Free cash flow: $164M
Free cash flow · +276% year on year · trailing twelve months to Q1 2026
Operating margin: 12%
Operating margin · trailing twelve months to Q1 2026

Details›

Every series Ryufin has for KNSA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$754M	+57%	Q1 2026
Net income	$73M	−531%	Q1 2026
EPS	$0.91	−464%	Q1 2026
Gross margin	89%	n/a	Q1 2026
Operating margin	12%	n/a	Q1 2026
Net margin	9.8%	n/a	Q1 2026
ROE	7.5%	n/a	Q1 2026
ROA	5.6%	n/a	Q1 2026
Free cash flow	$164M	+276%	Q1 2026
P/E	87.7	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.